September 10th: Adocia Oral Presentation at the Annual Congress of the Société Francophone du Diabète (SFD)

Adocia to Present Results of the 1st Phase Ib Study of M1Pram (ADO09) at the Annual Congress of the Société Francophone du Diabète (SFD)

Adocia will deliver an oral presentation on the 1st Phase Ib Study of M1Pram (ADO09) (pramlintide insulin) at the Annual Congress of the Société Francophone du Diabète. The data were previously reported at the annual meeting of European Association for the Study of Diabetes et de l’Advanced Technologies & Treatments for Diabetes.

Details of the Upcoming Event (French only):

Oral Presentations: Thérapeutique – insulinothérapie

ADO09, une co-formulation de l’analogue d’amyline pramlintide et de l’analogue d’insuline humaine A21G, réduit la glycémie post-prandiale en comparaison à l’insuline lispro chez le diabétique de type 1. Orateur : Dr.  Grégory MEIFFREN.

(ADO09, a co-formulation of amylin analog pramlintide and human insulin analog A21G, reduces postprandial blood sugar compared to insulin lispro in type 1 diabetes. Orator: Dr.  Grégory MEIFFREN)

Date: September 10, 10:30pm – 12 :00pm CEST

Virtual Event: Registration

This initial Phase 1b study paved the way for a more advanced study, recruiting 40 patients who used M1Pram as an outpatient for three weeks compared to insulin aspart. These results were the subject of a press release on April 23, 2020.